DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Russell - 2 There's - 1 Covid - 1 Peter Micca - 1 AbbVie - 1 Emraclidine - 1 Myers Squibb - 1 Karuna - 1
Top related locs:
Albemarle Covid Bristol XEN1101 Acadia Tema Crown Luxembourg
Top related orgs:
Xenon Pharmaceuticals - 4 UBS - 2 Institute for Health Metrics - 1 Deloitte - 1 Cerevel Therapeutics - 1 Karuna Therapeutics - 1 Bristol Myers - 1 Leerink Partners - 1

Search resuls for: "Xenon Pharmaceuticals"


5 mentions found


☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
  + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com   time to read: +14 min
There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."
Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema
☆ Stocks making the biggest moves midday: Foot Locker, Okta, Carnival, Shopify and more
  + stars: | 2023-11-27 | by ( Brian Evans | ) www.cnbc.com   time to read: +3 min
Carnival — Shares added 1% after being upgraded to buy from hold by Melius Research . Crown Castle — The telecommunications stock jumped nearly 4% following an activist push for change at Crown Castle. Shares of Crown Castle are down 20% this year. Okta — Shares of the software company dropped 3% Monday after JMP Securities downgraded Okta to market perform. Teva Pharmaceuticals — U.S.-traded shares jumped 3% after an upgrade from UBS to buy from neutral.
Persons: Locker, Josh Weinstein, Melius, Okta, JMP, Albemarle —, Etsy, TD Cowen, —, Alex Harring, Hakyung Kim, Sarah Min, Michelle Fox, Jesse Pound, Darla Mercado Organizations: Citi, Melius Research, Crown, Elliott Investment Management, Sunday, JMP Securities, Albemarle, Battery Tech, U.S, Teva Pharmaceuticals —, UBS, Xenon Pharmaceuticals, —, Adobe Analytics Locations: Crown, Albemarle
☆ 'Incredibly compelling': The pros love small-cap stocks right now. Here are their top picks
  + stars: | 2023-09-21 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +4 min
Matt Orton, chief market strategist at Raymond James Investment Management, was the latest to urge investors to "strategically add" to small-cap stocks right now. Tom Ognar, senior portfolio manager at Allspring Global Investments, said small- and mid-cap stocks look the "most incrementally interesting" among growth stocks. "We're very attuned to the valuation discounts currently being afforded to small- and mid-cap stocks after protracted periods of underperformance relative to large-cap stocks," he said. It screened for the best small-cap stocks to play an economic recovery. RBC Capital Markets also released, in a September note, an updated list of what it called "high conviction" U.S. small-cap growth recommendations.
Persons: Matt Orton, Russell, CNBC's, Orton, Tom Ognar, Ognar, CNBC'S, Valvoline, it's, — CNBC's Michael Bloom Organizations: Raymond James Investment Management, Allspring Global Investments, . Bank of America, Microsystems, Technologies, RBC Capital Markets, Automotive, RBC, Clearwater Analytics, Clearwater, Xenon Pharmaceuticals
☆ These 11 funds have performed as well as tech stocks over the past 5 years
  + stars: | 2023-07-28 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +4 min
Look beyond tech But there are opportunities beyond tech: Morningstar data reveals the funds outside of tech and growth sectors that have also outperformed over the last five years. Top holdings include Home Depot, Johnson Controls International, Floor & Décor and Trane Technologies. Guinness Atkinson Alternative Energy Fund : This fund picks companies in the alternative energy sector, with at least half of the business dedicated to renewable energy or energy efficiency. Global X Lithium and Battery Tech ETF : The ETF comprises lithium producers and lithium battery makers — all essential to electric vehicles. Top holdings include United Airlines, Marathon Oil, Tyson Foods, Best Buy, and Synchrony Financial.
Persons: James Demmert, Hubbell, MasTec, Invesco Russell, Russell, Vanguard Baillie Gifford Organizations: Street Research, U.S . Federal, Morningstar, Enphase Energy, Fidelity, Housing, Home, Johnson, Trane Technologies, Guinness Atkinson Alternative Energy Fund, Schneider, NextEra Energy, Shelton Sustainable Equity Fund, Bunge, Battery Tech ETF, Samsung SDI, Trust, Industrial Renaissance, SPX Technologies, Sterling Infrastructure, Global, U.S . Infrastructure Development, Holdings, Rockwell Automation, United Rentals, Deere, Co, United Airlines, Marathon Oil, Tyson Foods, Synchrony, Heptagon, Equity Fund, Xenon Pharmaceuticals, TransMedics, FTAI Aviation, Vanguard, Moderna, Alnylam Pharmaceuticals, Coursera, Water Resources, Nasdaq, Water Locations: Luxembourg, Eaton, Albemarle
☆ Buy this little-known and underappreciated biopharma stock with nearly 60% upside, Goldman Sachs says
  + stars: | 2022-12-14 | by ( Samantha Subin | ) www.cnbc.com   time to read: +1 min
Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs says. The stock, he said, could jump 58% from Tuesday's close, given the bank's price target, and offers investors "innovation and blockbuster potential in an overlooked neuro category." Those gains would come even after a solid 24% gain this year and near 8% gain this month." And Xenon has solid balance sheet, Choi said. "Although pricing power will likely be limited, we think [the drug's] differentiated profile ... combined with good launch execution portends blockbuster FOS sales in the mostly generic epilepsy category," Choi wrote.
0 next >>
Total: 5